Skip to main content

Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial.

Journal articles  - Journal Article
Diggs, MR; Chu, SM; Fitch, KV; Olefsky, M; Watanabe, MG; Erlandson, KM; Lu, AB; Bloomfield, GS; Currier, JS; Curran, A; Eckard, AR; Smith, GHR ...
Published in: AIDS
April 1, 2026

BACKGROUND: There is limited evidence concerning the relationship between cardiometabolic characteristics and health-related quality of life (HRQoL), and potential effects of statin therapy among people with HIV (PWH). METHODS: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) enrolled PWH aged 40-75 years on antiretroviral therapy (ART) with low-to-moderate ASCVD risk. Coronary computed tomography angiography assessed coronary plaque among a subset of participants in the REPRIEVE Mechanistic Substudy at baseline and 24 months. The Short Form-36-Item Health Survey Version 2 was collected at baseline, and physical (PCS) and mental (MCS) component summary scores were determined. We explored the relationship of PCS and MCS with cardiometabolic characteristics, coronary atherosclerosis, and assessed change in score by treatment group (pitavastatin vs. placebo). RESULTS: Of 733 participants, median age was 51 years, 84% were male, 34% were Black non-Hispanic, and median years diagnosed with HIV was 15. At baseline, for participants randomized to pitavastatin vs. placebo the median PCS was 54.5 (Q1, Q3: 46.9, 57.7) vs. 54.1 (47.5, 58.0), and the median MCS was 52.9 (44.1, 57.6) vs. 52.8 (44.0, 57.9). In fully adjusted analyses, older age, Black non-Hispanic race/ethnicity, ART regimen class, elevated BMI, and cigarette smoking were associated with lower PCS. No clear trends were apparent with MCS. Between baseline and month 24, declines in PCS and MCS were minimal with no apparent difference by treatment group. CONCLUSIONS: Among this cohort of ART-treated PWH, baseline cardiometabolic risk factors were associated with worse self-reported physical HRQoL, with no apparent effect of statin therapy. TRIAL REGISTRATION: REPRIEVE; NCT02344290; https://clinicaltrials.gov/study/NCT02344290.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

April 1, 2026

Volume

40

Issue

4

Start / End Page

428 / 439

Location

England

Related Subject Headings

  • Virology
  • Quality of Life
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • HIV Infections
  • Female
  • Atherosclerosis
  • Anti-Retroviral Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Diggs, M. R., Chu, S. M., Fitch, K. V., Olefsky, M., Watanabe, M. G., Erlandson, K. M., … Grinspoon, S. K. (2026). Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial. AIDS, 40(4), 428–439. https://doi.org/10.1097/QAD.0000000000004401
Diggs, Marissa R., Sarah M. Chu, Kathleen V. Fitch, Maxine Olefsky, Maya G. Watanabe, Kristine M. Erlandson, Alex B. Lu, et al. “Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial.AIDS 40, no. 4 (April 1, 2026): 428–39. https://doi.org/10.1097/QAD.0000000000004401.
Diggs MR, Chu SM, Fitch KV, Olefsky M, Watanabe MG, Erlandson KM, et al. Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial. AIDS. 2026 Apr 1;40(4):428–39.
Diggs, Marissa R., et al. “Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial.AIDS, vol. 40, no. 4, Apr. 2026, pp. 428–39. Pubmed, doi:10.1097/QAD.0000000000004401.
Diggs MR, Chu SM, Fitch KV, Olefsky M, Watanabe MG, Erlandson KM, Lu AB, Bloomfield GS, Currier JS, Curran A, Eckard AR, Smith GHR, Sponseller CA, Fichtenbaum CJ, Malvestutto CD, Aberg JA, Foldyna B, Taron J, Karady J, Zanni MV, Douglas PS, Ribaudo HJ, Lu MT, Grinspoon SK. Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial. AIDS. 2026 Apr 1;40(4):428–439.

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

April 1, 2026

Volume

40

Issue

4

Start / End Page

428 / 439

Location

England

Related Subject Headings

  • Virology
  • Quality of Life
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • HIV Infections
  • Female
  • Atherosclerosis
  • Anti-Retroviral Agents